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Introduction
The oral route is the most favourable route for drug administration due to its ease of administration and minimal invasiveness. However, orally administered drug products are exposed to a number of potential barriers between administration and systemic exposure, such as dissolution of solid particles and potential precipitation in the gut lumen, permeation through the gut membrane, and intestinal and hepatic first pass metabolism. These processes can have a big impact on the ability to predict in vivo performance of drug products. The ability to anticipate the impact of these processes is of great importance in drug and formulation development.
The Innovative Medicines Initiative (IMI) Oral Biopharmaceutical Tools (OrBiTo) project aims to improve upon knowledge of oral drug absorption through the development of new methodologies and refinement of existing tools available in oral biopharmaceutical development. Through four workpackages (WP1-4), the OrBiTo project aims to improve on the tools for evaluating physico-chemical characterisations of active pharmaceutical ingredients (APIs), the development and characterisation of drug product formulations, better understanding of the human intestinal environment, and the in silico models for integrating these different aspects into quantitative and qualitative predictions of oral drug exposure (Lennernas et al., 2014) . In our previous work we demonstrated the setup of the OrBiTo database of APIs and an overview of the results of the simulation exercise to evaluate the predictive performance of three established PBPK software packages (Margolskee et al., 2017a; Margolskee et al., 2017b) .
Here we present an analysis of the prediction success with a focus on the impact of compound specific properties and other factors that may influence the outcome of predictions of oral drug exposure. For example, acid/base nature, as well as lipophilicity, are thought to play important roles in dissolution, absorption, and disposition, and are often used as input parameters of the PBPK model to dynamically calculate solubility in the different segments of the GI tract and account for the influence of prandial state on the drug solubility, dissolution rate and permeation rate due to the concentration of bile salts assuming different diffusion for free and micelle-bound drug (Miller et al., 2011) . Weak bases may be subject to precipitation in the high pH of the intestinal environment after dissolving in the low pH of stomach acid. The highly ionised state of acids in the intestinal lumen may increase solubility, but also hinder permeation through the phospholipid membranes of the intestinal wall. Acids and bases have the potential to distribute differently into tissues in the body, depending upon the tissue composition and their affinity for different phospholipids; in silico predictions of volume of distribution account for tissue composition and these differences between acids and bases (Rodgers and Rowland, 2006) . Lipophilicity may also affect dissolution in aqueous media, and highly lipophilic compounds can be subject to enhanced solubilisation by bile salts (Mithani et al., 1996) , an area which has the potential for error within the PBPK framework, especially if solubility in biorelevant media are not measured experimentally.
The Biopharmaceutics Classification System (BCS), as a classic categorisation of compounds into high and low solubility and high and low permeability, has been used extensively to qualitatively predict in vivo oral drug behaviour. In contrast, PBPK has the potential to quantitatively describe the qualitative dynamics indicated by the BCS classification and this can be tested by comparing the predictive abilities of PBPK for the different classes of compounds. For example, for PBPK to be at least as successful as the BCS benchmark, it should be able to distinguish differences in bioavailability between high and low permeable compounds, and differences in relative bioavailability between high and low soluble compounds.
Methods
Inclusion criteria were employed in order to select APIs from the OrBiTo API database for the simulation exercise. The criteria were primarily based on the minimum set of parameters necessary to simulate a compound using the PBPK absorption model in the different software packages and included the availability of: molecular weight, LogP/D, fraction unbound in human plasma (fup), any clearance source scalable to human, in vitro permeability with reference compounds, at least one measure of solubility and available clinical data following per oral administration of the given drug. Of the 83 APIs in the OrBiTo database at the start of the exercise, 43 satisfied the inclusion criteria. For more details on the API selection process and comparison of the simulation set with the entire database, see companion paper (Margolskee et al., 2017a) .
A large scale evaluation of the predictive performance of existing in silico methods was undertaken. Three software packages, GastroPlus™ (Simulations Plus Inc., Lancaster, CA), Simcyp® (Certara, Sheffield, UK) and GI-Sim (AstraZeneca, London, UK), were employed to produce bottom-up predictions for all of the 43 APIs in the simulation set. Each participating institution generated predictions for all available clinical study arms for the APIs that they had been allocated. A certain degree of overlap in API allocation was allowed to test for user differences. Limited standard operating procedures were provided for Simcyp and GISim, however, most decisions on parameter data selection and simulation setup were left to the individual modellers at each institution. For more details on the procedure for performing the simulations see companion paper (Margolskee et al., 2017b) .
Predictive performance of the PBPK software packages was evaluated through comparison of typical pharmacokinetic (PK) parameters between simulated and observed values. These PK parameters were calculated as described in Part 2 (Margolskee et al., 2017b) . The presented PK parameters included: AUC 0-t,last (area under the curve from time zero to last measured time point), AUC 0-Inf (AUC from time zero extrapolated to time infinity), C max (maximum concentration in plasma), t max (time of peak concentration), t 1/2 (terminal half-life), CL (clearance), CL/ F (oral apparent CL), V d (volume of distribution), V d /F (oral apparent V d ), MTT (mean transit time), MRT (mean residence time), F oral (bioavailability), MAT (mean absorption time), F rel (relative bioavailability), relative C max , and relative AUC.
Summary statistics for describing the overall performance of the simulations were decided upon through consensus between the involved institutions and calculated as specified in our companion paper (Margolskee et al., 2017b) . Statistical metrics included: % within two, three and ten-fold of observed, Average Fold Error (AFE), Absolute AFE (AAFE), Pearson regression coefficient (R) and Concordance Correlation Coefficient (CCC) (Lin, 1989; Poulin et al., 2011) . The analysis presented in this manuscript focused on single dose and fasted state study arms only (excluding: multiple dose and fed state simulations).
Grouping based on drug-specific properties
APIs were separated based on drug-specific properties of interest to evaluate the potential impact on the performance of the models. Properties investigated include molecular weight (MW), acid/base nature, lipophilicity (logP and/or logD), BP, fu p , BCS class, dose number (D o ) and estimated f a from scaled human effective permeability (P eff ).
Groupings for acid/base nature included acid, ampholyte, neutral, weak base, and strong base categories, where strong bases shad at least one pKa N7. For each of the properties MW, logP, logD, BP and fu p , the APIs were separated into four quartiles. Quartiles for each of these properties are displayed in Table 1 . The logD values used in the groupings were the reported logD values taken at the pH closest to 7.4 for each API. In the case for thirty five of the APIs this was pH 7.4, while for the remaining eight APIs the closest pH ranged from 6.5 to 8 (Margolskee et al., 2017a) .
Grouping based on D o and f a followed the BCS cut-offs of D o ≤ 1 and D o N 1, and f a b 0.9 and f a ≥ 0.9. Grouping based on BCS class was carried out according to the reported BCS class of the compounds in the database, or if this was not available, an estimated BCS classification was assigned from f a based on scaled human Peff, and dose number based on maximum reported dose and aqueous solubility. For further details of these calculations, see companion paper (Margolskee et al., 2017a) .
Geometric mean FEs were calculated for each API, averaging over API specific study arms (to account for APIs with different numbers of simulated study arms). APIs were categorised according to properties of interest, and summary statistics of the PK parameters were calculated for each group.
In order to test for interdependencies in the API parameters that may impact the interpretation of the results, Pearson correlation coefficients were calculated for each pairwise combination of relevant quantitative parameters. The parameters analysed were MW, logP, logD, highest basic pKa, lowest acidic pKa, logit(fu p ), log(BP-0.5), logit(f a ), and log(D o ), where logit(x) = log(x/(1-x)). The transformations for fu p , BP, f a and D o were chosen so the transformed variables would be approximately normally distributed, allowing for more meaningful correlation estimates. Correlations N0.7 in magnitude were considered strong, while correlations between 0.5 and 0.7 were considered moderate.
Results and Discussion
Inspection of correlations between API properties revealed a strong negative correlation between logP and logit(fu p ) and a strong positive correlation between lowest acidic pKa and log(BP -0.5) (Fig. 1) . Moderate positive correlations included logP vs logD, logD vs lowest acidic pKa, highest basic pKa vs log(BP -0.5), and logit(fu p ) vs log(BP -0.5). Moderate negative correlations included highest basic pKa vs log(D o ) and logP vs log(BP -0.5). Several of these correlations are not surprising, such as logP and logD which both relate to lipophilicity, and fu p and BP which relate to plasma and blood binding properties. The high correlation between logP and plasma protein binding has also been well documented (Yamazaki and Kanaoka, 2004) . These correlations should be taken into consideration when interpreting the results of this exercise.
Sections 3.1-3.3 detail the influence of compound properties of interest on the predictive performance of different PK parameters including AUC 0-t,last , F oral , F rel , C max , CL or CL/F and V d or V d /F. A summary of the findings is included in Table 2 . Section 3.4 includes discussion around the interpretation of the results, and next steps. Analysis applied to the predictive performance of additional PK parameters can be found in the Supplementary Material.
Physicochemical properties
The correlations between physico-chemical properties and the success in predictions were investigated for different parameters including acid/base nature and lipophilicity, while MW was also investigated, no trends were apparent.
Acid-base Nature
Predictions of oral AUC 0-t,last for neutral compounds and strong bases generally performed well, displaying 80.0% and 92.3% of predictions within three-fold of observed data. Further, low variability was observed for FEs for neutral APIs and strong bases, with calculated AAFEs of 1.92 and 1.63, respectively. Reasonable correlations between predicted and observed were noted, where neutrals and strong bases displayed R coefficients of 0.89 and 0.93, and CCC of 0.34 and 0.93 ( Fig. 2A-C) .
Poor predictions of AUC 0-t,last were observed for acids with 10.0% and 20.0% within two and three-fold for p.o. simulations and a high variability with AAFE of 6.33 ( Fig. 2A-C) . This poor predictive performance may be due to issues in predicting disposition, as both F oral and F rel between p.o. formulations and solutions were generally well predicted (80% and 100% within two-fold) (Fig. 2D, G) . The AUC 0-t,last predictions of p.o. simulations for acidic compounds displayed a low bias with AFE of 1.16 (Fig. 2B) , indicating the presence of both over-and underpredictions, while i.v. formulations displayed an overall overestimation as compared to observed data. This overprediction in i.v. exposure seems to be a combined underprediction of both CL (AFE of 0.346) and V d (AFE of 0.564) for acids (Table A5 and Table A6 ).
A slight negative bias of F oral was observed for predictions of acids with an AFE of 0.580 (1.72-fold underprediction) and poor correlation (R of −0.570 and CCC of −0.480). This could be related to a potential underestimation of permeability of acidic compounds, an overestimation of the impact of ionisation on permeation, or a lack of information on intestinal transporters. It could also be related to an underestimation of solubility of weak acids due to less than optimal intestinal model pH settings or an underestimation of contribution of bile micelles. However, it could also be due to a small number of poor predictions as the percent within two-fold was considered high at 80.0%.
Poor predictions of F oral were seen for weak bases (25.0% within two-fold), showing a tendency towards overprediction (AFE 1.48), somewhat high source of variability (AAFE 2.46) and poor correlation between predicted and observed, with an R of − 0.56 and CCC of − 0.296 ( Fig. 2D-F) . A slight overprediction of F oral was observed, whereas F rel between p.o. formulations and solution was (Fig. 2H ). This trend in predictions for weak bases may be due to insufficient data to inform precipitation of the formulation, as few APIs had information regarding precipitation in vitro (Margolskee et al., 2017a) . C max was best predicted for neutral compounds, strong and weak bases with 60.0%, 53.8% and 45.5% predicted with two-fold of observed data, respectively. Neutral compounds and weak bases further displayed the strongest correlation metrics (R and CCC of 0.783 and 0.644, for weak bases; R and CCC of 0.922 and 0.749 for neutral APIs; Table A2 ).
3.1.2. Lipophilicity 3.1.2.1. LogP. Investigating the impact of logP on predictions of AUC 0-t,last revealed predictions for APIs in the second quartile range of logP (Q2: 2.545-3.3) to show a tendency towards better performance as compared to either extremes, with 55.6% within two-fold error, AFE of 1.14, AAFE of 2.17, and R of 0.862 and CCC of 0.836 (Fig. 3) . Both low logP (Q1: − 0.72-2.54) and high logP (Q4: 4.49-7.75) APIs performed poorly compared to the Q2, displaying a lack of correlations, with an R of 0.0411 and 0.0489 for Q1 and Q4, respectively, and a CCC of 0.0183 and 0.0481 (Fig. 3) .
APIs in the upper quartile of logP generally gave underpredictions of F oral (AFE of 0.477 for Q4), while those in the third quartile gave overpredictions (AFE of 2.21). APIs with lower logP gave the least biased predictions (AFE of 0.819 and 0.920 for Q1 and Q2, respectively). Predictions of F oral for APIs with measured logP were fairly consistent in their correlation with observed, with an R of 0.671, 0.464, and 0.588 for Q1, Q3, and Q4. APIs without measured logP gave highly inconsistent predictions when comparing to observed data with an R of −1 (Fig. 3D-F) . BCS II and IV: F rel predictions displayed negative bias as compared with overprediction for BCS I and III (freely soluble compounds). f a f a ≥ 0.9: Displayed a lower bias, higher precision and better correlation metrics for predictions of F oral as compared to the f a b 0.9 group. Relative AUC between p.o. formulations and solution was predicted best for APIs in the third quartile of logP (Q3: 3.3-4.49), with 100% within two-fold (n = 4), AFE of 1.06, low variability with AAFE of 1.19, and strong correlation with R of 0.99 and CCC of 0.87 ( Fig. 3G-I ). Relative AUC showed underpredictions on average for both APIs with low logP (Q1) and high logP (Q4) compared to APIs with middle range logP (Q2 and Q3), displaying AFE of 0.57 and 0.54 (1.75 and 1.85-fold underpredictions) for Q1 and Q4, respectively, compared to 0.74 (1.35-fold underprediction) and 1.06, for Q2 and Q3 (Fig. 3H ). Underpredictions of F rel for compounds with logP values in Q4 suggest inadequate models for solubility and dissolution of highly lipophilic compounds, possibly underperforming bile enhancement models or lack of solubility data generated in biorelevant media for highly lipophilic compounds. Interestingly, Q4 showed high correlations between predicted and observed, with R of 0.985, but relatively low CCC of 0.510, suggesting the predictions were in the right direction but on the wrong scale (Fig. 3I) .
The average predictive performance for V d or V d /F for i.v. and p.o. simulations was relatively unbiased for low logP compounds with AFE ranging from 0.917 to 1.14 for Q1 through Q3, while a general trend of overprediction was observed for highly lipophilic compounds (AFE of 2.43 for Q4) ( Fig. 4 and Table A6 ). This may be related to the in silico methods utilised for predicting distribution into tissues, which varied between users and software. It is well known that in silico methods for predicting V ss , such as the Poulin and Theil and Rodgers and Rowland model (Poulin and Theil, 2000; Rodgers et al., 2005; Rodgers and Rowland, 2006) , overpredict the volume of distribution for highly lipophilic compounds. Alternative models have been developed to account for the overprediction in V ss for highly lipophilic compounds (Berezhkovskiy, 2004; Poulin and Haddad, 2012) , and these were employed to some extent in the modelling of APIs for the OrBiTo simulation exercise at the modellers discretion. Further analysis will explore user differences such as this in an effort to test the performance of alternative methods.
3.1.2.2. LogD. Prediction performance of AUC 0-t,last for p.o. simulations for APIs in the first quartile of logD (Q1: −1.45-1.29, n = 7) was poor, with 14.3%, 28.6% and 57.1% within two, three and ten-fold error, vs. 33.4%, 52.3%, and 90.7%, for the APIs in Q2-Q4 combined (Fig. 5) . AUC 0-t,last was overpredicted on average for APIs in Q1, with AFE of 2.19 vs. 1.15 for Q2-Q4 combined. Further, Q1 showed high variability with AAFE of 7.60 vs. 3.29 for Q2-Q4, and low correlation between predicted and observed with R of −0.239 and CCC of −0.083 (Fig. 5) .
Predictions for AUC 0-t,last F oral were poor for APIs in Q1 of logD, displaying AFE of 0.418 (or 2.38-fold underprediction; n = 3; vs. AFE of 1.14 for Q2-Q4; n = 9), high variability with AAFE of 4.17 (vs. 1.87 for Q2-Q4), and poor correlation between predicted and observed with R of − 0.855 and CCC of −0.706. However, more APIs in Q1 had predictions of F oral within two-fold compared with Q2-Q4 (66.7% vs. 55.6%), and less within three and ten-fold, 66.7% and 66.7%, vs. 88.9% and 100%, for Q2-Q4, indicating the results may be skewed by a single outlier (Fig. 5D-F) .
Predictions for F rel between p.o. and solutions seemed to perform better for lower quartiles of logD, with 100% within two-fold for Q1, 75.0% for each of Q2 and Q3, and 50.0% for Q4. On average, the bias for the different quartiles appeared comparable, with AFE of 0.868, 0.829, 1.09, and 0.606 for Q1, Q2, Q3, and Q4, respectively. The variability in the predictions appeared to increase with increasing logD, with AAFE of 1.35, 1.70, 1.66, and 1.88 for Q1, Q2, Q3 and Q4. Additionally, correlation between predicted and observed F rel declined with increasing logD (R of 0.466, 0.136, 0.0683 and −0.392 and CCC of 0.136, 0.125, 0.0662, and −0.179 for Q1, Q2, Q3, and Q4; Fig. 5G-I) .
Predictions of p.o. AUC 0-t,last performed poorly for APIs for which logP was not given (n = 8) compared to those for which logP was reported (n = 35). While the overall average performance of the APIs without logP was very good at predicting AUC 0-t,last (AFE of 1.11), the variability was high, with an AAFE of 4.91 (vs. 2.90 for APIs providing logP) and 12.5% fell within 2 fold (vs. 42.9%), and additionally, there was poor correlation between predicted and observed AUC 0-t,last with R of − 0.0936 and CCC of − 0.0913 (Fig. 3) . In contrast, the group of APIs for which logD was not reported performed very well in predicting AUC 0-t,last , with 53.3% and 73.3% within two and three-fold error, vs. 28.7% and 46.4%, for APIs where logD was provided (Q1-Q4 combined). APIs not reporting logD also had relatively unbiased estimates and reasonable variability compared with APIs reporting logD. Correlation between predicted and observed was also very high with R of 0.846 and CCC of 0.834 (Fig. 5) .
Plasma and blood binding values
In this section, the connection between blood and plasma binding properties and prediction performance was investigated for different pharmacokinetic parameters. Summary statistics were investigated for APIs divided into BP quartiles, and divided into fu p quartiles (Table 1) .
Q1 and Q2 for BP showed poor predictions of AUC 0-t,last , with a low percentage falling within n-fold, high variability, and poor correlations between predicted and observed (Fig. 6 ). Clearance predictions also showed high variability and poor correlation for lower values of BP ( Fig. 6D-F , and Table A5 ). A similar trend was seen for fu p , where Q1 and Q2 generally underperformed compared with Q3 and Q4 with low correlations between predicted and observed (Fig. 7C ). There was a moderate correlation between fu p and BP for our dataset (Fig. 1) , and a great overlap between APIs of the lowest BP quartiles and the lowest fu p group (fu p b 0.01). Low BP indicates lack of uptake into red blood cells, which may reflect the high plasma protein binding in these cases. The underestimations of clearance observed for lower fu p (highly protein bound) compounds could be explained by unknown mechanisms for the transfer of highly lipophilic drugs into cells from proteins, as a modest positive relationship between logP and percent bound to protein in plasma (or negative relationship between logP and fu p ) has been documented in the literature (Yamazaki and Kanaoka, 2004) , similarly a strong correlation was observed between logP and fu p for our dataset (Fig. 1) .
De Buck 2007 investigated the prediction of hepatic clearance using two different methods, method 1 using the traditional formula involving fu p /BP and fu inc , and method 2 where the effects of fu p /BP and fu inc were assumed to cancel each other out. The second method performed considerably better at predicting in vivo hepatic clearance from in vitro CL int , potentially through unintentionally compensating for the inherent underprediction in CLint when scaling from HLMs or human hepatocytes (Hallifax et al., 2012) . The results of De Buck 2007 and the relationship we have observed here between low BP and high variability, and low fu p and high variability in the prediction of clearance may be related.
Blood to plasma ratio (BP)
Simulated APIs were divided into four quartiles (Q1 to Q4; Table 1 ) based on average simulated blood-to-plasma ratios (BPs). The percent within n-fold increased with increasing BP quartile, where 0.00, 33.3, 50.0 and 63.6% fell within two-fold for Q1 through Q4, respectively, 27.3, 44.4, 66.7 and 81.8% within three-fold, and 72.7, 77.8, 100, and 100% within ten-fold. Similarly, the quartiles showed increasing precision with increasing BP with AAFE of 5.91, 4.46, 2.12, and 2.09 for Q1 through Q4. While Q1 showed a relatively low bias with AFE of 0.951, Q2 through Q4 continued the trend of better performance with increasing BP, with AFE of 2.13, 1.57, and 0.98. Q1 and Q2 also showed poor correlation between predicted and observed with R of 0.0147 and −0.112 and CCC of 0.0136 and −0.101. In contrast, Q3 and Q4 displayed good correlation between predicted and observed data with R of 0.825 and 0.921 and CCC of 0.727 and 0.908 (Fig. 6A-C) .
When examining the prediction of CL and CL/F for p.o. and i.v. simulations, there was a tendency of better performance for the higher quartiles of BP. Q1 displayed 0.00, 18.2 and 81.8% of predictions within two, three and ten-fold with similar results for Q2. Q3 and Q4 showed higher frequency within n-fold, with 50.0, 58.3 and 100% for Q3, and 63.6, 81.8, and 100% for Q4 falling within two, three and ten-fold. Q2 displayed the largest bias (AFE: 0.298, or a 3.36-fold underprediction) and poorest precision (AAFE: 7.00), whereas Q1 displayed the lowest AFE at 1.02 and Q4 the lowest AAFE at 2.05. Correlations between predicted and observed CL or CL/F progressively improved with increasing BP quartiles (R: 0.197, 0.189, 0.537, 0.793 for Q1 through Q4 and CCC: 0.0464, 0.123, 0.243, 0.790 for Q1 through Q4; Fig. 6D -F, and Table A5 ).
Investigating the impact of BP on the performance of predicting C max revealed an overall trend of improvement towards compounds with higher BP, for instance CCC ranged from 0.224 for Q1 to 0.636 for Q4. Similarly, improvements were seen in the bias (AFE Q1-Q4: 0.247-0.75) and precision (AAFE Q1-Q4: 7.36-2.73) with increasing BP (Table A2) .
Fraction unbound in plasma (fu p )
Examining the predictive performance of simulated p.o. AUC 0-t,last in relation to simulated average fu p neglected to show any apparent trends. However, there was an increase in performance in terms of R and CCC with increasing percentiles, with R values of − 0.0658, 0.00985, 0.527, and 0.866 for Q1 through Q4, and CCC of − 0.0614, 0.00851, 0.400, and 0.810 for Q1 through Q4, respectively (Fig. 7) .
BCS Classification
For BCS class I compounds, 37.5% of APIs displayed a predicted average oral AUC 0-t,last within two-fold, with 87.5% of predictions falling within ten-fold, BCS class II compound displayed a similar level of percentage within two, three and ten-fold. BCS IV APIs displayed a lower degree of predictability with 33.33% falling within two-fold and 77.8% within ten-fold; whereas analysis of BCS class III was limited to two APIs and could therefore be considered undetermined (Fig. 5A) . BCS class I, II and IV displayed a low AFE, 0.796, 1.55, and 1.47, respectively, and AAFE increased with increasing BCS class, 2.81, 3.30 and 4.00 (Fig.  5B) . With respect to correlation parameters, BCS class I compounds outperformed the remaining classes, displaying an R value of 0.850 and a CCC value of 0.837 (Fig. 8) .
F oral predictions for BCS classes III and IV (low permeable compounds) displayed negative bias as compared with BCS I and II (high permeable compounds), displaying AFE of 0.357 for BCS III and IV combined (n = 5) and 1.54 for BCS I and II combined (n = 12; Fig. 8E ). Similarly, F oral predictions for estimated f a b 0.9 displayed negative bias with AFE of 0.499 (n = 6) vs. 1.47 for APIs with estimated f a ≥ 0.9 (Fig. 9E ). This underprediction of F oral for low permeable compounds could potentially indicate an oversensitivity of the models to in vitro permeability measurements, improper intestinal surface area estimates, underestimates of colonic absorption and/or lack of intestinal transporter information. Simulations for highly permeable compounds (f a ≥ 0.9) in general performed better than those for low permeable compounds in terms of predictions of p.o. AUC 0-t,last , C max and F oral . This is possibly not surprising, as for highly permeable compounds f a will saturate at a value close to1.0, thus providing limited information on prediction performance of the model. Looking at lower permeable compounds gives a better indication of the (lack of) precision and accuracy of scaling and modelling of permeability.
F rel predictions for BCS classes II and IV (low soluble compounds) displayed negative bias, with AFE of 0.677 (a 1.48-fold underprediction) as compared with 1.20 overprediction for BCS I and III (high soluble compounds) (Fig. 5H) . Similarly, compounds with D o N 1 (n = 21) displayed AFE of 0.681 vs. 1.38 for compounds with D o ≤ 1 (Fig. 10E) . While the number of F rel predictions for compounds in the higher soluble category was small (4 based on reported BCS and 3 based on calculated D o ), the underpredictions of F rel for low soluble compounds suggest over sensitivity of the dissolution models to aqueous solubility. However, this could also be due to a lack of available measurements of solubility in biorelevant media, as 72.1% of the simulation set were missing this data (Margolskee et al., 2017a) .
Estimated fraction absorbed from in vitro permeability assay
Permeability-limited APIs (f a b 0.9) displayed an improved prediction of p.o. AUC 0-t,last as compared to highly permeable APIs (f a ≥ 0.9) with regards to within two-fold with calculated values of 46.7 and 32.1%, respectively; whereas highly permeable compounds displayed a higher frequency within ten-fold as compared to permeability limited APIs with 96.4 and 73.3% (Fig. 9A ). Oral predictions of AUC for highly permeable APIs displayed slightly higher accuracy and precision compared to permeability-limited APIs with AFEs of 1.22 and 1.47, AAFEs of 3.08 and 3.47 (Fig. 9B) . Further, highly permeable APIs displayed a better correlation between predicted and observed AUC compared with low permeable compounds (R: 0.199 and − 0.0389 and CCC: 0.195 and −0.0110; Fig. 9C ).
Predictions of F oral in relation to estimated f a gave comparable percent within two and three-fold whereas APIs with higher estimated f a ≥ 0.9 displayed a larger percentage within ten-fold as compared to the f a b 0.9 group (100% vs. 83.3%; Fig. 9D ). The f a ≥ 0.9 group displayed a lower bias and higher precision as compared to the f a b 0.9 group, with AFE of 1.47 and 0.499, respectively and AAFE of 1.83 and 2.53 (Fig. 9E) . Correlation coefficients R and CCC suggested similar correlations between predicted and observed F oral for the two groups with a slight favour towards f a ≥ 0.9 (R: 0.517, CCC: 0.439) as compared to f a b 0.9 (R: 0.451, CCC: 0.373; Fig. 9F ).
Dose number (D o )
Examining the predictive success of oral AUC 0-t,last in relation to dose number grouping revealed a comparable percentage within two, three and ten-fold. Freely soluble APIs displayed 37.5, 62.5 and 87.5% within two, three and ten-fold and solubility-limited compounds displayed 37.1, 54.3 and 88.6% within two, three and ten-fold, respectively. Freely soluble drugs displayed improved AFE and AAFE as compared to solubility-limited compounds, with an AFE of 0.796 (or 1.26-fold underprediction) compared to 1.46 for D o ≤ 1 and D o N 1 and AAFE of 2.81 and 3.31. There was an apparent difference in R and CCC for predicted vs. observed oral data for APIs divided based on the D o cut-off point, with calculated R coefficients of 0.850 and 0.0684 for D o ≤ 1 and D o N 1, and CCC of 0.837 and 0.0640 (Fig. 10 ).
There were only 86 simulations and 3 APIs in the D o ≤ 1 group for which F rel was obtainable, whereas there were 594 simulations and 21 APIs in the D o N 1 enabling calculation of F rel . Thus, there were a very limited number of comparators in the D o ≤ 1 group. However, the two groups displayed comparable percent within two, three, and ten-fold (66.7%, 66.7% and 100%, respectively for D o ≤ 1 and 76.2%, 81% and 100% for D o N 1), and comparable precision with AAFE of 1.66 and 1.67 for D o ≤ 1 and D o N 1. One area of noticeable difference was in the overall bias of the F rel predictions, for which the D o N 1 group displayed an overall negative bias with AFE of 0.681 (a 1.47-fold underprediction) and the D o ≤ 1 group displayed a positive bias with an AFE of 1.38 (Fig. 10) .
Freely soluble APIs (compounds with D o ≤ 1) displayed slightly poorer performance in C max prediction with respect to percent within N-fold, AFE and AAFE, while displaying a minor improvement in correlation between predicted and observed C max , (R and CCC of 0.627 and 0.533, respectively, vs. 0.442 and 0.438 for solubility limited compounds; Table A2 ).
Interpretation
The purpose of this large-scale simulation exercise was to evaluate and identify areas for improvement in the current PBPK modelling approach to predicting oral exposure, bioavailability and biopharmaceutics effects. The analysis of the simulation exercise managed to highlight both cases where the PBPK absorption modelling approach performed in line with clinical data and cases within the drug-specific parameter space where simulations deviated from the expected.
There are challenges in interpreting the results of this analysis, as performance is a function of data, model and modeller. Data to inform parameters may be of varied quality and in many cases was lacking, and clinical data may be misrepresentative due to low sample sizes or high variability. Models may fail to appropriately describe gastrointestinal physiology, morphology and the underlying processes governing F oral . The modellers' interpretation and selection of input parameters can also significantly impact performance.
One should be cautious when interpreting the impact of drugspecific properties on the success of PBPK predictions of oral exposure in the current study, due to the heterogeneity and variable nature of the analysed dataset. There was lack of uniformity in reported API parameter data, with data sources and availability of preclinical and clinical data differing widely between APIs. There was also an intention to examine the impact of user differences on the prediction success, thus modellers were relatively unrestricted in their selections of input data and modelling approaches. Some of these decisions included: Selection of clearance sources for extrapolation, methods for estimating volume of distribution, permeability assays used to inform P eff , selection of solubility and/or dissolution sources and formulation properties. Further, simulations were carried out only for APIs which fulfilled minimal criteria for available data with a degree of missingness allowed for certain parameters (BP and logP) which were replaced with estimates. The high degree of missingness together with a lack of information regarding experimental protocols could be attributed to historical compounds for which key information was not generated, including for example information on the contribution of metabolic pathways, main route of elimination and biorelevant solubility. However, the prevalence of historic compounds within the OrBiTo database could not be confirmed due to its blinded nature. Certain elements of missing information may also be due to lack of data or the inability to disclose data to outside parties. Other reasons for missing information may be due to unclear standards for the information required and/or desired for Fig. 9 . Statistical metrics of prediction success of oral AUC 0-t,last (A-C) and F oral (D-F) as compared to the biopharmaceutics classification system (BCS) cut-off point for permeability (f a = 0.9) divided into permeability-limited (f a b 0.9) and highly permeable (f a ≥ 0.9) active pharmaceutical ingredients (APIs). prospective PBPK modelling, e.g. lack of pre-clinical data for a number of APIs. The key missing data which may influence model performance will be addressed throughout the OrBiTo project through EFPIA effort in generating the data and updating their dataset.
Limitations of the simulation exercise put into question whether a true evaluation of PBPK absorption model performance was in fact successful. One can argue that without a full dataset of input parameters to inform the model the boundaries cannot fully be tested. The utilisation of a minimum set of input parameters in most cases will result in an advanced model collapsing down to a simpler one, e.g. a lack of particle size distributional parameters for a given formulation will collapse down to modelling a single uniform particle size (measured or assumed).
However, the broad spectrum analysis of this exercise was able to identify several areas for future model improvement and key inputs needed for building a robust model, which may not have been possible with a smaller scale evaluation of a more data-rich compound set (Table 3 ). Cautious interpretation of the current findings can be used to inform future directions for improvement of in silico models and available inputs, which should then be evaluated with more targeted test sets. For example, a set of data-rich compounds of high lipophilicity and low aqueous solubility, but relatively high in vivo relative bioavailability could be used to test improvements in in silico biorelevant solubility predictions. A set of data-rich BCS III compounds with high solubility and low fraction absorbed could be used to evaluate improvements of intestinal surface area estimates and the contribution of colonic absorption.
Several tasks are identified in OrBiTo WP4 and across the whole consortium to address the points highlighted in this paper. One task addresses the dynamic calculation of bile salt concentration in the GI tract, while another is making changes to the GI tract physiology, and proposing a more biorelevant model for gastric emptying, lumen and mucosal liquid volumes, together with a gallbladder emptying model. Other projects include proposing new models for supersaturation and precipitation, new algorithms for passive and active permeability and finally a new model for lymphatic absorption.
In parallel to these model improvements, the learning of where models perform well and where they need to improve will also guide the future data collection work or data completion work needed from the EFPIA companies. The database will be complemented with missing information on existing drug records such as rCYP in vitro characterisation of Vmax and Km of the main enzymes involved in the drug metabolism when pre-systemic extraction is suspected, measurements of log P, pKa, aqueous solubility or solubility in biorelevant media. This work also highlights the need for more EFPIA examples of drugs that are relevant for intestinal absorption and oral formulation modelling such as poorly absorbed compounds and weak bases with their precipitation characterisation. All of these examples if they exist could be fed into the OrBiTo database in order to enrich the dataset with more relevant examples.
Conclusion
The results of this exercise suggest that PBPK modelling of oral bioavailability generally performs well for well-behaved compounds (e.g. neutral or strong base, mid-range logP (2.545 to 3.3), high permeability, high solubility, BP N0.64 and fu p N 0.05). However, as shown in this study, an increasing level of complexity, e.g. solubility and permeability limitations, and increasing complexity of delivery system, were met with decreased prediction performance. In such scenarios, modelling efforts may rely more heavily on quality of input data, model assumptions, and modeller experience. It would therefore be advisable to take into account the increasing degree of uncertainty on prediction success.
For interpreting the results of this study, one must take into perspective the level of availability, detail and quality of data that was used to generate simulations as well as the limitation in contact that could occur between modellers and API owners which would normally occur in the pharmaceutical industry. As such, this approach therefore can be regarded as an opportunistic blinded modelling exercise driven by availability of parameter data. It is the opinion of the authors' that future similar simulation exercises should strive for a more synergistic approach between data gathering and model building in order to ensure the exercise to produce relevant results. Further analysis of the simulation output is required to explore the performance of formulation and food effects. Areas for Improvement Checklist.
✔ Areas for Improvement Checklist
Fa b90% -improve scaling of in vitro to in vivo permeability, and in silico models of intestinal surface area and transporters Low Aqueous Solubility and/or High LogP -improve in silico models and in vitro availability of biorelevant solubility and dissolution Acids -improve predictions of CL, Vd and permeability Weak bases -improve in silico predictions of precipitation and availability of in vitro data No reported LogP -improve availability of logP measurements Low BP and/or low fu p -investigate influence of blood and plasma binding on underpredictions of hepatic CL for highly plasma bound compounds 
